Can a smartphone app keep cirrhosis patients out of the hospital?

NCT ID NCT03564626

Completed Knowledge-focused Sponsor: Virginia Commonwealth University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested whether a health app (Patient Buddy and EncephalApp) plus scheduled follow-up calls and visits could reduce avoidable hospital readmissions within 30 days in 232 cirrhosis patients. Patients and their caregivers were trained on the app and received daily contact, counseling, and follow-up. The goal was to see if this extra support helps prevent unnecessary returns to the hospital.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Patient Buddy and EncephalApp (health app) plus scheduled follow-up calls and visits
What this could lead to: If it works, this approach could help cirrhosis patients avoid unnecessary hospital readmissions by improving monitoring and support at home.
What could go wrong: This is a completed trial, but the results are not yet widely confirmed. The app-based approach may not work for all patients, especially those less comfortable with technology.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CIRRHOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver Fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CIRRHOSIS

Contacts and locations

Locations

Hunter Holmes McGuire VA Medical Center

Richmond, Virginia, 23249, United States
Mayo Clinic

Rochester, Minnesota, 55905, United States
Virginia Commonwealth University

Richmond, Virginia, 23298, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.